Extended cognitive recovery in down syndrome mice via sustained release of AM404 from microplates

Abstract Neurodevelopmental disorders (NDDs) are often characterized by cognitive deficits associated with hippocampal dysfunction and microglial activation. In the in the Dp(16) and Ts65Dn mouse models of Down syndrome (DS), paracetamol (PRC) has been shown to modulate microglia-mediated neuroinflammation and rescue memory tasks. However, the high doses of PRC typically required limit its long-term use due to dose-related toxicity, including reported hepatotoxicity and cardiotoxicity. Here, we employed polymeric microPLates (µPL) made of poly(lactic-co-glycolic acid) (PLGA) to sustain delivery of AM404 (AM404-µPL), the primary PRC metabolite with glia-directed anti-inflammatory activity. Using a top-down fabrication approach, AM404 was loaded into square-shaped µPL and evaluated for activity in vitro and in vivo . Free AM404 enhanced microglial metabolism and exerted anti-inflammatory effects comparable to paracetamol in activated microglia from Dp(16) mice. In vivo , low-dose free AM404 (1 mg/kg for three days) improved cognitive deficits in DS mice without affecting control mice; whereas higher doses (10 mg/kg) impaired cognition in healthy mice and had no effect on DS mice. In contrast, a single injection of AM404-µPL improved DS mice cognition for two weeks without harming healthy mice. Notably, after one week, cognitive abilities in DS mice matched those achieved with repeated low-dose of free AM404. These findings support AM404 sustained delivery as a strategy to maintain therapeutic efficacy while reducing dosing frequency and toxicity, offering a promising approach for treating DS as well as other NDDs.

Authors

Institutions

Publication Details

Journal
Drug Delivery and Translational Research
Published
2026-11-16
DOI
https://doi.org/10.1007/s13346-026-02246-y
Primary Topic
Down syndrome and intellectual disability research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Extended cognitive recovery in down syndrome mice via sustained release of AM404 from microplates

Laura Cancedda, Greta Avancini, Andrea Armirotti, Stefania Mamberti et al.
1 links
Drug Delivery and Translational Research
Down syndrome and intellectual disability research
article

Extended cognitive recovery in down syndrome mice via sustained release of AM404 from microplates

Laura Cancedda, Greta Avancini, Andrea Armirotti, Stefania Mamberti, Sine Mandrup Bertozzi, Corinne Portioli, Denise Murgia, Paolo Decuzzi, Raffaele Spanò, Bianca Martins Estevão
article en

Abstract

Abstract Neurodevelopmental disorders (NDDs) are often characterized by cognitive deficits associated with hippocampal dysfunction and microglial activation. In the in the Dp(16) and Ts65Dn mouse models of Down syndrome (DS), paracetamol (PRC) has been shown to modulate microglia-mediated neuroinflammation and rescue memory tasks. However, the high doses of PRC typically required limit its long-term use due to dose-related toxicity, including reported hepatotoxicity and cardiotoxicity. Here, we employed polymeric microPLates (µPL) made of poly(lactic-co-glycolic acid) (PLGA) to sustain delivery of AM404 (AM404-µPL), the primary PRC metabolite with glia-directed anti-inflammatory activity. Using a top-down fabrication approach, AM404 was loaded into square-shaped µPL and evaluated for activity in vitro and in vivo . Free AM404 enhanced microglial metabolism and exerted anti-inflammatory effects comparable to paracetamol in activated microglia from Dp(16) mice. In vivo , low-dose free AM404 (1 mg/kg for three days) improved cognitive deficits in DS mice without affecting control mice; whereas higher doses (10 mg/kg) impaired cognition in healthy mice and had no effect on DS mice. In contrast, a single injection of AM404-µPL improved DS mice cognition for two weeks without harming healthy mice. Notably, after one week, cognitive abilities in DS mice matched those achieved with repeated low-dose of free AM404. These findings support AM404 sustained delivery as a strategy to maintain therapeutic efficacy while reducing dosing frequency and toxicity, offering a promising approach for treating DS as well as other NDDs.

Drug Delivery and Translational Research
Italian Institute of Technology (IT), Stanford Medicine (US), Center for Clinical Research (United States) (US), Stanford University (US)
Istituto Italiano di Tecnologia, HORIZON EUROPE Marie Sklodowska-Curie Actions
Good health and well-being
Down syndrome and intellectual disability research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon